|Title||University of Virginia & Merck (UVA-LACC-PD201)|
|Principal Investigator/ Physician||Jennifer Scalici, MD|
|Contact Email||MCI Clinical Trials|
Protocol Title: "A Randomized Phase Ii Study of Chemoradiation and Pembrolizumab for Locally Advanced Cervical Caner."
Inclusion Criteria: Histologically confirmed invasive squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma of the uterine cervix, stages IB2, IIA, IIB, IIIB and IVA, Stage IB1 with + pelvic or para0aortic nodes base on MRI also eligible; no evidence of distant metastases; recurrent cervical cancer is not eligible; ECOG performance status of 0-2.
Exclusion Criteria: Malignancy within the prior 5 years (exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has undergone potentially curative therapy); diagnosis of immunodeficiency; know history of HIV, Hepatitis B/C, active TB, inflammatory bowel disease; hypersensitivity to pembrolizumab or any of its excipients; active autoimmune disease that has required systemic treatment in the past 2 years; known history or evidence of pneumonitis; known active CNS metastases and/or carcinomatous meningitis.
Clinical Trials.Gov Link: https://clinicaltrials.gov/ct2/show/NCT02635360?term=UVA-LACC-PD201&rank=1
© 2018 USA Health